|
- There is a growing body of evidence on the treatment of DR-TB in children, and most studies find that children have excellent outcomes and fewer adverse events than adults when promptly identified and started on treatment with SLDs.
- The risks and benefits of each drug should be carefully considered in designing a regimen.
- In general, anti-TB drugs should be dosed according to body weight.
- Frank discussion with family members is critical, especially at the outset of therapy.
- Monthly monitoring of body weight is therefore especially important in pediatric cases, with adjustment of doses as children gain weight.
- Recent evidence shows that fluoroquinolones are safe to use in children with MDR-TB or exposed to MDR-TB. (Ref)
- Treatment of MDR-TB in children should be managed in consultation with an MDR-TB specialist.
|
